- Sage Therapeutics Inc SAGE and Biogen Inc BIIB have scored their first but narrow win after signing their $3.1 billion deal last year in November.
- SAGE-324, the second major molecule in the pact, cleared a Phase 2 trial for essential tremor (ET), a progressive disorder that causes involuntary muscle movement.
- After 29 days, patients in the SAGE-324 cohort had experienced a 36% reduction in upper limb tremor amplitude, compared to a 21% reduction in the placebo group.
- The difference caused the trial to hit its primary endpoint with a p-value of 0.049. In patients with severe symptoms at baseline, upper limb tremor amplitude fell 41%.
- And the results come with 38% of the patients dropping out from the trial, and most patients reduced their dose because they had difficulty tolerating the drug.
- A statistically significant correlation between upper limb tremor scores and activities of daily living (ADL) results at all time points.
- The trial was not fully powered to examine ADL, a key measure for ET patients, but SAGE-324 numerically beat placebo.
- Safety and tolerability was an issue for some patients, however. The company started patients on 60-mg doses with the option to down-titrate to 45 mg or 30 mg in the event of tolerability issues at the higher dose.
- 62% of participants down-titrated. 38% of patients discontinued dosing altogether.
- Sleepiness or drowsiness was the most common treatment-emergent adverse event, affecting 68% of patients on SAGE-324.
- Price Action: SAGE shares are down 2.77% at $74.49, while BIIB shares dipped 1.28% at $264.74 in the market trading session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
